Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

PMID:
19883527
[PubMed - indexed for MEDLINE]
Free Article
2.

Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.

McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC.

Br J Psychiatry. 2009 Mar;194(3):273-7. doi: 10.1192/bjp.bp.107.045245.

PMID:
19252159
[PubMed - indexed for MEDLINE]
Free Article
3.

The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Pediatr. 2012 Jun 19;12:78. doi: 10.1186/1471-2431-12-78.

PMID:
22712630
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners.

McCarthy S, Wilton L, Murray M, Hodgkins P, Asherson P, Wong IC.

Health Qual Life Outcomes. 2013 Feb 22;11:22. doi: 10.1186/1477-7525-11-22.

PMID:
23432851
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
[PubMed - indexed for MEDLINE]
6.

[Prescribing of stimulants for ADHD in Nordland County].

Asheim H, Nilsen KB, Johansen K, Furu K.

Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2360-2. Norwegian.

PMID:
17895938
[PubMed - indexed for MEDLINE]
Free Article
7.

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.

Sasané R, Hodgkins P, Meijer W.

Curr Med Res Opin. 2010 Nov;26(11):2565-74. doi: 10.1185/03007995.2010.518131. Epub 2010 Sep 23.

PMID:
20863165
[PubMed - indexed for MEDLINE]
8.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
[PubMed - indexed for MEDLINE]
9.

Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.

McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC.

Drug Saf. 2009;32(11):1089-96. doi: 10.2165/11317630-000000000-00000.

PMID:
19810780
[PubMed - indexed for MEDLINE]
10.

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.

Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.

Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.

PMID:
20178404
[PubMed - indexed for MEDLINE]
11.

The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI.

Eur J Clin Pharmacol. 2013 Mar;69(3):589-98. doi: 10.1007/s00228-012-1344-0. Epub 2012 Jul 19.

PMID:
22811260
[PubMed - indexed for MEDLINE]
12.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

J Manag Care Pharm. 2012 Nov-Dec;18(9):676-89.

PMID:
23206211
[PubMed - indexed for MEDLINE]
Free Article
13.

Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Psychiatry. 2012 Dec 5;12:219. doi: 10.1186/1471-244X-12-219.

PMID:
23216881
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

PMID:
23801529
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands.

Hodgkins P, Sasané R, Meijer WM.

Clin Ther. 2011 Feb;33(2):188-203. doi: 10.1016/j.clinthera.2011.03.001.

PMID:
21497704
[PubMed - indexed for MEDLINE]
16.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
[PubMed - indexed for MEDLINE]
17.

Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.

van den Ban E, Souverein P, Swaab H, van Engeland H, Heerdink R, Egberts T.

J Child Adolesc Psychopharmacol. 2010 Feb;20(1):55-61. doi: 10.1089/cap.2008.0153.

PMID:
20166797
[PubMed - indexed for MEDLINE]
18.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

PMID:
16796929
[PubMed - indexed for MEDLINE]
Free Article
19.

Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators.

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

PMID:
22519922
[PubMed - indexed for MEDLINE]
20.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

PMID:
17874862
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk